It may only be a matter of time before psychedelics become a go-to treatment for millions suffering with some sort of mental illness.
Another bill clears to study psychoactive drugs to treat vets with PTSD
The Texas Legislature has approved a study that will look at using psilocybin as a treatment for veterans struggling with Post-Traumatic Stress Disorder.
Enveric Envisions Using Mushrooms and Cannabis to Help Patients
The cannabis biotech company explains why the acquisition of MagicMed makes sense, additional capital raises and the Psybrary.
Interest in the medical use of psychoactive drugs increasing
Many venture capitalists are looking for investment opportunities on the frontiers of research into psychedelic drugs.
Mental Health Care May Never be the Same With Psychedelics
There’s been a substantial proof psychedelics can help with issues such as depression, anxiety, addiction, obsessive compulsive disorder, and obesity.
Medicine Company Approved To Study Sublingual Psilocybin For Major Depressive Disorder
Psychedelic drug development company Cybin will launch a phase two clinical trial on its sublingual formulation of psilocybin for patients with Major Depressive Disorder later this year.
Health Canada Approves Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms
Mydecine receives regulatory approval to expand its psilocybin mushroom cultivation operations.
MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
MindMed executes an MOU to access the drug delivery system of Israel-based Nextage Therapeutics.
Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives
NASDAQ-listed Enveric Biosciences is merging with private psychedelics company, Magic Med Industries.
Wesana Health Expands Research Leadership Team with Mark Wingertzahn, PhD as Chief Scientific Officer
Wesana's new Chief Scientific Officer has deep experience in the pharmaceutical industry with Pfizer and GSK.
Robust Capital Flows Continue For Private Psychedelics Companies
Public psychedelics companies have radically scaled-back capital raising due to low share prices. But institutional investors are still pumping large amounts of cash into private players.
Former Senate Majority Leader Tom Daschle Appointed Special Adviser to Field Trip Health Ltd.
Field Trip appoints a former high-ranking Democrat as a Special Advisor to the company.
